At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Armodafinil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue
In Brief
A Phase 2 clinical trial evaluating Armodafinil and placebo for Brain Tumors and 3 related conditions. Completed, enrolled 54 participants across 1 site.
Detailed Summary
RATIONALE: Armodafinil may help relieve fatigue and improve quality of life in patients with cancer receiving radiation therapy to the brain. PURPOSE: This clinical trial is studying how well armodafinil works in treating fatigue caused by radiation therapy in patients with primary brain tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartAug 2010
Primary CompletionJan 2013
TodayJul 2026
First PostedDec 15, 2009
Enrollment StartAug 1, 2010
Primary CompletionJan 8, 2013
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.5 years ago
Interventions
Armodafinildrug
Given orally
placeboother
Given orally